+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07480733

Phase II Study of JS212 and JS213 Alone or Combined to Treat Advanced Malignant Solid Tumors

Led by Shanghai Junshi Bioscience Co., Ltd. · Updated on 2026-05-29

410

Participants Needed

1

Research Sites

49 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics, and early effects of the drugs JS212 and JS213, both alone and in combination, in adults with advanced malignant solid tumors. This Phase II clinical trial focuses on patients with serious cancers such as renal cell carcinoma, prostate cancer, urothelial carcinoma, and melanoma who have not responded to prior treatments. The trial aims to assess how well these treatments work and their impact on tumor response rates. The study includes five treatment groups JS212 alone, JS213 alone, JS212 combined with JS213, JS212 combined with JS207, and JS212 combined with toripalimab. All drugs are given by intravenous infusion on the first day of each 21-day cycle. Participants receive the assigned treatment according to their group and continue under close monitoring. Participants will undergo evaluations that include tumor imaging to measure response, safety assessments for side effects, laboratory tests, and monitoring of overall health status. Researchers will track objective response rate and other outcomes like progression-free survival and duration of response for up to six years. The study involves regular visits for treatment administration and safety checks, with participants followed long-term to observe outcomes and any adverse effects.

CONDITIONS

Brief Title

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Research Team

Y

Yuteng Shen, Project manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here